Anticoagulation and antiplatelet therapy post coronary artery bypass surgery

Area of Science:

• Cardiovascular Surgery
• Pharmacology
• Clinical Outcomes

Background:

• Coronary artery bypass grafting (CABG) is a standard treatment for multivessel coronary heart disease.
• Graft failure following CABG is a significant concern, increasing patient morbidity and mortality.

Purpose of the Study:

• To review clinical outcomes of antiplatelet and anticoagulant therapies post-CABG.
• To evaluate the effectiveness of dual antiplatelet regimens compared to aspirin alone.
• To assess the role of anticoagulation in preventing graft failure and adverse cardiac events.

Main Methods:

• Literature review of clinical outcomes following antiplatelet and anticoagulant therapy after CABG.
• Analysis of evidence regarding specific antiplatelet agents (clopidogrel, ticagrelor, prasugrel) in combination with aspirin.
• Evaluation of studies on anticoagulants (warfarin, rivaroxaban) post-CABG.

Main Results:

• Evidence is varied regarding the benefit of clopidogrel or ticagrelor combined with aspirin for graft patency and clinical outcomes.
• Dual antiplatelet therapies may offer protective effects, particularly in off-pump CABG.
• Warfarin and rivaroxaban showed no protection against graft failure but decreased long-term major adverse cardiac events.

Conclusions:

• Further research is needed to clarify the optimal use of dual antiplatelet therapy post-CABG.
• Specific patient groups may benefit from adding thienopyridines or anticoagulants to aspirin.
• Anticoagulation is likely indicated only for post-CABG patients at high risk for future ischemic events.